Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aspen

- PMLiVE

Novartis funds chronic urticaria app and patient community

My Hives has been developed, and will be run, by Exco InTouch

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

EISAI

Eisai gets green light for Lenvima in kidney cancer

New drug awarded breakthrough and priority review status by FDA in RCC

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

Novartis building

As promised, Novartis’ Entresto is a ‘slow burner’

Inverts typical sales pattern with faster uptake of the drug in Europe than in the US

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

Novartis kicks back against US corruption charges

Investigation ‘explodes’ with US government information request on 79,000 physicians events

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

Novartis building

Novartis claims FDA breakthrough status for leukaemia treatment

Designation could speed up development and access for Novartis’ PKC412

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links